港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

維昇藥業-B

47.550

-0.150-0.31%

成交量：54.21萬

成交額：2,634.15萬

市值：54.21億

市盈率：-24.43

高：50.450

開：47.750

低：45.800

收：47.700

資料載入中...

總覽公司新聞公告

維升藥業-B03月27日主力淨流入58萬元散户資金拋售

維升藥業-B03月26日主力淨流出300萬元散户資金買入

“生長發育第一股”維升藥業登陸港股：市值78億港元，去年前三季虧1.3億元

對壘“東北藥茅”，反向Newco藥企攪局百億黃金賽道

《新股》維升藥業－Ｂ(02561.HK)全日收68.8元

阿斯达克财经

公司研究室IPO週報：維升藥業成“港股生長激素第一股”；宏信超市通過聆訊零售業務下滑

公司研究室

《新股》維升藥業－Ｂ(02561.HK)半日收67.2元低上市價2.3%

阿斯达克财经

“生長激素第一股”維升藥業港股上市，近三年利潤持續虧損

維升藥業今日IPO，破發2%

市值76億！紅杉投出一個IPO

港股“生長發育第一股”維升藥業-B(02561)正式掛牌，募資總額逾1億美元，罕見新老股東同台支持

新股首日 | 維昇藥業-B首日平開，公開發售獲72.64倍認購，一手中籤率6.27%

老虎资讯综合

生長發育第一股！維升藥業登陸港交所開盤微漲、總市值超77億港元

異動解讀 | 維昇藥業-B上市首日盤中大跌5.52%，投資者熱情或已降温

《新股》維升藥業－Ｂ(02561.HK)首日開報68.8元

阿斯达克财经

生長發育第一股！今日，維升藥業正式登陸港交所

Insight数据库

港股IPO動態：今日維升藥業上市

《新股》維升藥業(02561.HK)公開發售超購逾71倍一手中籤率6.27%

阿斯达克财经

【新股IPO】維升藥業-B(02561)定價68.8港元一手中籤率6.27%

維升藥業-B(02561)每股發售價68.8港元香港公開發售獲72.64倍認購

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02561/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"維昇藥業-B","latestPrice":47.55,"timestamp":1753085318016,"preClose":47.7,"halted":0,"volume":542100,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"未開盤","change":-0.15,"latestTime":"07-21 16:08:38","open":47.75,"high":50.45,"low":45.8,"amount":26341495,"amplitude":0.097484,"askPrice":49,"askSize":2300,"bidPrice":47.55,"bidSize":2900,"shortable":0,"etf":0,"ttmEps":-1.946273,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1753147800000},"marketStatusCode":0,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":47.7,"openAndCloseTimeList":[[1753061400000,1753070400000],[1753074000000,1753084800000]],"volumeRatio":22.036585231484235,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":22.036585231484235,"shares":113999999,"dividePrice":0,"high":50.45,"amplitude":0.097484,"preClose":47.7,"low":45.8,"week52Low":39.25,"pbRate":"20.53","psRate":"1783.30","week52High":69.15,"institutionHeld":0,"latestPrice":47.55,"committee":0.115385,"eps":-1.946273,"divideRate":0,"volume":542100,"delay":0,"ttmEps":-1.946273,"open":47.75,"prevYearClose":68.8,"prevWeekClose":47.7,"prevMonthClose":45.3,"prevQuarterClose":45.3,"fiveDayClose":44.7,"twentyDayClose":48.7,"sixtyDayClose":48.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522329855","title":"維升藥業-B03月27日主力淨流入58萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329855?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 16:25","pubTimestamp":1743063955,"startTime":"0","endTime":"0","summary":"03月27日, 维升药业-B股价涨1.20%，报收54.75元，成交金额2248万元，换手率0.38%，振幅12.48%，量比0.00。维升药业-B今日主力资金（超大单+大单）净流入58万元，上一交易日主力净流出300万元。该股近5个交易日下跌20.57%，主力资金累计净流入251万元；近20日主力资金累计净流入251万元，其中净流入天数为3日。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327175625a6a5ef79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327175625a6a5ef79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":0},{"id":"2522844948","title":"維升藥業-B03月26日主力淨流出300萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2522844948","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522844948?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 16:16","pubTimestamp":1742977010,"startTime":"0","endTime":"0","summary":"03月26日, 维升药业-B股价跌9.83%，报收54.10元，成交金额3014万元，换手率0.47%，振幅13.75%，量比0.00。维升药业-B今日主力资金净流出300万元，上一交易日主力净流入150万元。该股近5个交易日下跌21.51%，主力资金累计净流入192万元；近20日主力资金累计净流入192万元，其中净流入天数为2日。该股主力净额占比0.05%，港股市场排名2573/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250326170016a6a47b9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250326170016a6a47b9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":1},{"id":"2521514406","title":"“生長發育第一股”維升藥業登陸港股：市值78億港元，去年前三季虧1.3億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2521514406","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521514406?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 18:06","pubTimestamp":1742551560,"startTime":"0","endTime":"0","summary":"在第四次递表后，维升药业终于成功登陆港股。港股上市首日，维升药业盘中最高跌5.81%，最终平收，市值78.38亿港元。2022年和2023年，公司期内综合亏损总额分别为2.89亿元、2.49亿元。2025年2月更新的招股书显示，2024年前九个月公司亏损额为1.3亿元。该药已在美国、欧盟获批上市。据弗若斯特沙利文数据，中国人生长激素市场规模由2018年的40亿元迅速增至2023年的116亿元，年复合增长率为23.9%，预计到2030年将持续增至人民币286亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032118123694bc569e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032118123694bc569e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","HSCEI","02561"],"gpt_icon":1},{"id":"2521644286","title":"對壘“東北藥茅”，反向Newco藥企攪局百億黃金賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2521644286","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521644286?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 17:08","pubTimestamp":1742548083,"startTime":"0","endTime":"0","summary":"被誉为百亿黄金赛道的生长激素领域，又迎来一位搅局者，且还是一家国外药企“反向”Newco到中国市场的企业。01反向Newco轻资产模式开局若要说过去一年中国创新药行业讨论度最高的话题，“Newco”这一吸引了诸多国内药企入局的出海模式绝对有一席之位。2021年、2022年该药已先后在美国、欧盟上市，中国市场则于2024年初向国家药监局递交上市申请并获受理，预计可在2025年下半年获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321203638a43cb374&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321203638a43cb374&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":1},{"id":"2521787473","title":"《新股》維升藥業－Ｂ(02561.HK)全日收68.8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2521787473","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521787473?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 16:15","pubTimestamp":1742544900,"startTime":"0","endTime":"0","summary":"维升药业－Ｂ(02561.HK) 首日挂牌，开报68.8元；最高/低分别见69.15/64.8元，全日收68.8元，全日成交340.86万股，涉资2.28亿元。(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142909241_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142909241_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1426807/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02561"],"gpt_icon":0},{"id":"2521539421","title":"公司研究室IPO週報：維升藥業成“港股生長激素第一股”；宏信超市通過聆訊零售業務下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2521539421","media":"公司研究室","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521539421?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 14:59","pubTimestamp":1742540359,"startTime":"0","endTime":"0","summary":"港股3月18日，卓正医疗向港交所递交上市申请。3月20日，宏信超市通过港交所聆讯。按产品划分，宏信超市零售业务收入分为食品、非食品、烟草三大部分。然而，由于该公司终止烟草业务经营，因此，2024年前三季度，该项收入降至0元，对零售业务收入造成冲击。“港股生长激素第一股”维升药业今日上市，总市值约77亿港元2025年3月21日，维升药业正式在港交所上市。此次IPO，维升药业所得款项净额为6.72亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321150029a69e8596&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321150029a69e8596&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["07226","02561","HSCEI","HSTECH"],"gpt_icon":1},{"id":"2521445684","title":"《新股》維升藥業－Ｂ(02561.HK)半日收67.2元 低上市價2.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521445684","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521445684?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 12:05","pubTimestamp":1742529900,"startTime":"0","endTime":"0","summary":"维升药业－Ｂ(02561.HK) 首日挂牌，开报68.8元。最高/低分别见69.15/64.8元，半日收67.2元，较上市价68.8元，低2.3%，半日成交249.51万股，涉资1.65亿元。(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142907811_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142907811_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1426728/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02561"],"gpt_icon":0},{"id":"2521410864","title":"“生長激素第一股”維升藥業港股上市，近三年利潤持續虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=2521410864","media":"界面","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521410864?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 12:00","pubTimestamp":1742529659,"startTime":"0","endTime":"0","summary":"中国生长激素市场潜力巨大，市场规模从2018年的40亿元增至2023年的116亿元，预计2030年达286亿元。维升药业的IPO之路可谓波折，2022年11月至2024年9月期间先后四次向港交所递交上市申请，最终通过聆讯。此次IPO将大幅改善维升药业财务情况。目前，维升药业依然亏损，2022年至2024年前9个月净亏损分别为2.9亿元、2.5亿元和1.3亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321120231a43c2155&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321120231a43c2155&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","HSCEI","02561"],"gpt_icon":1},{"id":"2521472059","title":"維升藥業今日IPO，破發2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521472059","media":"医药财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521472059?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 11:13","pubTimestamp":1742526839,"startTime":"0","endTime":"0","summary":"2025年3月31日，由安科生物、药明生物、维梧资本等作为基石投资者的维升药业在港交所成为IPO。IPO破发背后，折射出港股市场对创新药估值逻辑的重新校准。结语维升药业的IPO破发，既是创新药“估值泡沫”的理性回归，也是市场对其商业化能力的压力测试。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321164636a43c6ac5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321164636a43c6ac5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","BK1161","02561"],"gpt_icon":1},{"id":"2521446777","title":"市值76億！紅杉投出一個IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2521446777","media":"猎云网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521446777?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 11:01","pubTimestamp":1742526090,"startTime":"0","endTime":"0","summary":"3月21日，维升药业登陆港交所，发行价格为每股68.80港元，开盘平开；截至发稿每股跌1.74%至67.6港元，总市值76.01亿。维升药业拥有一款核心产品及两款其他在研候选药物。财务方面，由于尚无产品上市，2022年、2023年及2024年前三季度，维升药业尚未实现营业收入，净亏损分别为2.89亿元、2.50亿元和1.297亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321110157971e4988&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321110157971e4988&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":1},{"id":"2521448318","title":"港股“生長發育第一股”維升藥業-B(02561)正式掛牌，募資總額逾1億美元，罕見新老股東同台支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2521448318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521448318?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 10:10","pubTimestamp":1742523032,"startTime":"0","endTime":"0","summary":"3月21日，维升药业在香港联交所挂牌上市，发行价格为每股68.80港币。市场认购火爆，招股期截止时，维升药业公开发售部分预计获得72.64倍超额认购，国际发售部分同时获得1.65倍超额申购。这就意味着，维升药业将成为2025年第一家登陆港交所的创新药企，也将成为港股“生长发育第一股”。此次维升药业登陆港交所，或将成为重塑内分泌治疗标准的全球领跑者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1265217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4614","HSCEI","HSTECH","YANG","02561"],"gpt_icon":1},{"id":"1139250215","title":"新股首日 | 維昇藥業-B首日平開，公開發售獲72.64倍認購，一手中籤率6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139250215","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139250215?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 09:55","pubTimestamp":1742522103,"startTime":"0","endTime":"0","summary":"本周五， $维昇药业-B$ 上市首日平开，随后一度跌近6%，截至发稿报66.4港元，跌幅3.49%：公开发售阶段维昇药业-B获72.64倍超额认购，经回补、重新分配后，公开发售的发售股份最终数目为455.4万股股份，占发售股份总数的约40%。合共接获22345份有效申请，受理申请数目7498份，一手中签率6.27%。此外，国际配售阶段维昇药业-B获1.65倍超额认购，经回补、重新分配后，国际发售股份最终数目为683.1万股股份，相当于发售股份总数的60%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股首日 | 维昇药业-B首日平开，公开发售获72.64倍认购，一手中签率6.27%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"2521410949","title":"生長發育第一股！維升藥業登陸港交所開盤微漲、總市值超77億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2521410949","media":"地产k线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521410949?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 09:50","pubTimestamp":1742521817,"startTime":"0","endTime":"0","summary":"乐居财经 王敏3月21日，维升药业-B在港交所挂牌上市，成为港股市场生长发育第一股，摩根士丹利及Jefferies联席保荐，开盘微涨0.29%，总市值77.58亿港元。维升药业目前没有获准可作商业销售的产品，亦未从产品销售中产生任何收入。自成立以来的各年度及于往绩记录期间，维升药业均产生经营亏损。于2022年、2023年及截至2024年4月30日止四个月，维升药业的综合亏损总额分别为2.89亿元、2.5亿元及6032万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321095242a43bffb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321095242a43bffb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":1},{"id":"1199182642","title":"異動解讀 | 維昇藥業-B上市首日盤中大跌5.52%，投資者熱情或已降温","url":"https://stock-news.laohu8.com/highlight/detail?id=1199182642","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199182642?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 09:39","pubTimestamp":1742521181,"startTime":"0","endTime":"0","summary":"3月21日，内地生物制药公司维昇药业-B在港交所主板挂牌上市，然而开市后不久，该股便出现大幅下跌。盘中数据显示，维昇药业-B股价大跌5.52%，引发市场关注。根据此前公告，维昇药业-B以每股68.8港元的价格完成招股，募集资金净额约6.72亿港元。然而，上市首日的股价表现却未能延续这一热度。分析人士指出，维昇药业-B上市首日的大幅下跌可能反映了投资者情绪的快速转变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 维昇药业-B上市首日盘中大跌5.52%，投资者热情或已降温","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02561"],"gpt_icon":0},{"id":"2521841717","title":"《新股》維升藥業－Ｂ(02561.HK)首日開報68.8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2521841717","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521841717?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 09:35","pubTimestamp":1742520900,"startTime":"0","endTime":"0","summary":"维升药业－Ｂ(02561.HK) 暗盘昨日收63.85元。低上市价7.2%。今日首日挂牌，开报68.8元，开市时段成交177.82万股。(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191017105312335_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191017105312335_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1426635/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02561"],"gpt_icon":0},{"id":"2521446770","title":"生長發育第一股！今日，維升藥業正式登陸港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2521446770","media":"Insight数据库","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521446770?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 09:12","pubTimestamp":1742519531,"startTime":"0","endTime":"0","summary":"去年 1 月，维升药业向药监局提交了该产品的上市申请，预计今年下半年能够获批。精准聚焦+全面穿透商业化路径已经展开随着隆培促生长素上市进入倒计时，维升药业正以“精准制导”的策略全面铺开其商业化版图。以隆培促生长素为例，维升药业已经锁定约1000 家公立医院作为目标市场，包括所有主要儿童医院、主要的三级医院及部分儿科规模可观的二级医院。长期，维升药业计划建立内部生产能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321110344a43c138f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321110344a43c138f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":1},{"id":"2521490374","title":"港股IPO動態：今日維升藥業上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2521490374","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521490374?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 06:11","pubTimestamp":1742508682,"startTime":"0","endTime":"0","summary":"格隆汇3月21日｜今日维升药业(2561.HK)上市，舒宝国际(2569.HK)处于申购期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032106112694bb9437&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032106112694bb9437&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02569","02561","HSTECH","HSCEI"],"gpt_icon":0},{"id":"2521467683","title":"《新股》維升藥業(02561.HK)公開發售超購逾71倍  一手中籤率6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521467683","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521467683?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 01:40","pubTimestamp":1742492400,"startTime":"0","endTime":"0","summary":"维升药业－Ｂ(02561.HK)公布招股结果，香港公开发售接获72.64倍认购，一手(100股)中签率6.27%，认购2,000股获稳派一手。按回补机制，公开发售股份增至455.4万股，占发售总数40%。国际发售录得1.65倍认购。最终发售价68.8元，近下限定价，集资净额6.72亿元。股份预期周五(21日)挂牌。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250313082411569_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250313082411569_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1426557/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02561"],"gpt_icon":0},{"id":"2520346578","title":"【新股IPO】維升藥業-B(02561)定價68.8港元 一手中籤率6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520346578","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520346578?lang=zh_tw&edition=fundamental","pubTime":"2025-03-20 23:19","pubTimestamp":1742483984,"startTime":"0","endTime":"0","summary":"金吾财讯 | 维升药业-B(02561)公布招股结果，每股定价68.8港元。集资所得款项总额约7.83亿港元，净额约6.72亿港元。每手100股，一手中签率6.27%，认购20手可稳获一手。香港公开发售部分录得22,345份有效申请，认购额72.64倍；国际配售录得认购额1.65倍。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/YTdjODg5ZDM1NDI1NjgyNDQyMw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YTdjODg5ZDM1NDI1NjgyNDQyMw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1955575","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"2520450430","title":"維升藥業-B(02561)每股發售價68.8港元 香港公開發售獲72.64倍認購","url":"https://stock-news.laohu8.com/highlight/detail?id=2520450430","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520450430?lang=zh_tw&edition=fundamental","pubTime":"2025-03-20 22:26","pubTimestamp":1742480786,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)公布配发结果，公司全球发售1138.5万股股份，香港公开发售占40%，国际发售占60%。最终发售价为每股68.8港元，全球发售净筹约6.72亿港元。每手100股，预期股份将于2025年3月21日(星期五)上午九时正(香港时间)开始在联交所买卖。其中，香港公开发售获72.64倍认购，国际发售获1.65倍认购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1265092.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":71,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746460800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-07-18","current":-27.275886,"percent":0.493151,"low":-30.760225,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"high":-17.514985,"avg":-26.483178,"sd":2.802831,"marketCap":5434311412},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412}],"updateTime":1753130580340}}}